Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jeffrey Small"'
Autor:
Peter L. Kurczynski, Michael D. Johnson, Sheperd S. Doeleman, Kari Haworth, Eliad Peretz, Tirupati Kumara Sridharan, Byran Bilyeu, Lindy Blackburn, Don Boroson, Alexandra Brosius, Richard Butler, Dave Caplan, Koushik Chatterjee, Peter Cheimets, Daniel D'Orazio, Thomas M. Essinger-Hileman, Peter Galison, Ronald Gamble, Shahar Hadar, Tiffany Hoerbelt, Hua Jiao, Jens Kauffmann, Robert Lafon, Chung-Pei Ma, Gary Melnick, Nathan R. Newbury, Scott Noble, Daniel Palumbo, Lenny Paritsky, Dominic Pesce, Leonid Petrov, Jeff Piepmeier, Christopher J. Roberts, Bryon Robinson, Curt Shieler, Jeffrey Small, Neal Spellmeyer, Paul Tiede, Jaye Verniero, Jade Wang, Maciek Wielgus, Ed Wollack, George N. Wong, Guangning Yang
Publikováno v:
Kurczynski, P L, Johnson, M D, Doeleman, S S, Haworth, K, Peretz, E, Sridharan, T K, Bilyeu, B, Blackburn, L, Boroson, D, Brosius, A, Butler, R, Caplan, D, Chatterjee, K, Cheimets, P, D'Orazio, D, Essinger-Hileman, T M, Galison, P, Gamble, R, Hadar, S, Hoerbelt, T, Jiao, H, Kauffmann, J, Lafon, R, Ma, C-P, Melnick, G, Newbury, N R, Noble, S, Palumbo, D, Paritsky, L, Pesce, D, Petrov, L, Piepmeier, J, Roberts, C J, Robinson, B, Shieler, C, Small, J, Spellmeyer, N, Tiede, P, Verniero, J, Wang, J, Wielgus, M, Wollack, E, Wong, G N & Yang, G 2022, ' The Event Horizon Explorer mission concept ', Proceedings of SPIE, vol. 12180, 12100M . https://doi.org/10.1117/12.2630313
The Event Horizon Explorer (EHE) is a mission concept to extend the Event Horizon Telescope via an additional space-based node. We provide highlights and overview of a concept study to explore the feasibility of such a mission. We present science goa
The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors
Publikováno v:
Oncotarget
// Jeffrey Small 1 , Erik Washburn 2 , Karmaine Millington 2 , Junjia Zhu 3 and Sheldon L. Holder 1 1 Division of Hematology/Oncology, Penn State Hershey Cancer Institute, Hershey, PA, USA 2 Department of Pathology and Laboratory Medicine, Penn State
Autor:
Sheldon L. Holder, Jeffrey Small
Publikováno v:
Journal of Clinical Oncology. 35:452-452
452 Background: The majority of therapeutic agents used in renal cell carcinoma (RCC) target the vascular endothelial growth factor and mammalian target of rapamycin pathway. Exceptions include the immunotherapy agents interleukin-2 and nivolumab. To
Publikováno v:
ANZ Journal of Surgery. 81:303-303
Publikováno v:
Digestive Diseases & Sciences; Jul2006, Vol. 51 Issue 7, p1269-1276, 8p
Autor:
Jonathan A Lee, Paul Shinn, Susan Jaken, Sarah Oliver, Francis S Willard, Steven Heidler, Robert B Peery, Jennifer Oler, Shaoyou Chu, Noel Southall, Thomas S Dexheimer, Jeffrey Smallwood, Ruili Huang, Rajarshi Guha, Ajit Jadhav, Karen Cox, Christopher P Austin, Anton Simeonov, G Sitta Sittampalam, Saba Husain, Natalie Franklin, David J Wild, Jeremy J Yang, Jeffrey J Sutherland, Craig J Thomas
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0130796 (2015)
Phenotypic assays have a proven track record for generating leads that become first-in-class therapies. Whole cell assays that inform on a phenotype or mechanism also possess great potential in drug repositioning studies by illuminating new activitie
Externí odkaz:
https://doaj.org/article/1946423edacf41cd981806581d41073c